MISSION,VISIONANDVALUES

MISSIONThe EF Clif is intended to support high quality research and education on Acute-on-Chronic Liver Failure (ACLF), in order to improve the quality of life and to increase the survival of patients with liver cirrhosis.

VISIONOur aim is helping investigators to achieve their objectives and being a referent in ACLF research, in order to increase survival of patients with liver cirrhosis and improve their quality of life.

SERVICE INNOVATION HEALTH RESEARCH UNITY EDUCATION COMPROMISEQUALITY OF LIFEDEDICATION ACCURACY WELFARE DYNAMISM TRANSPARENCY COMMITMENT INDEPENDENCE

FACTS AND FIGURES

1,000

MORE THAN 1,000 INVESTIGATORS WORKING ON EF Clif SPONSORED SCIENTIFIC PROJECTS, FUNDED WITH MORE THAN

7,000,000 €/ year

225

CENTRES

COUNTRIES

Collaborators in Europe, North America, South America, Asia and Oceania 227 centres distributed in 3 international networks, in 44 countries around the world.

114

104

NUMBER
OF CENTRES

EASL - CLIF
ACLARA
ENTR

799

217

COLLABO-
RATORS

EASL - CLIF
ACLARA
ENTR

42%EASL-CLIF

339

44%ACLARA

45%ENTR

58%EASL-CLIF

460

56%ACLARA

121

55%ENTR

Number of countries involved in the EF Clif projects in each of the continents

2NORTH
AMERICA

28EUROPE

5ASIA

7LATIN
AMERICA

2OCEANIA

International networks

EASL-CLIF Consortium: Europe
ENTR-European Network for Translational Research: Europe and North America
Global Projects: Asia, Europe, North America, Latin America, Oceania

PATIENT COHORTS IN THE EF Clif STUDIES

PARTICIPATING HOSPITALS

RECRUITED PATIENTS

SAMPLES

ALIQUOTES

CANONIC
PREDICT
ACLARA
MICROB-PREDICT
DECISION

*Expected

2020 MILESTONES

MARCH

The recruitment of the ACLARA Study is completed

MAY

The REP-COVID Study is launched to collaborate in the search of a cure for the SARS-CoV-2 infection

JULY

The EASL Clif Consortium reached it’s highest number of partners: 114

FEBRUARY

Prof Rajiv Jalan was appointed as the Scientific Director of the EF Clif

MARCH

The recruitment of the ACLARA Study is completed

APRIL

Kick off of the DECISION Project, the new H2020 Adventure

MAY

The REP-COVID Study is launched to collaborate in the search of a cure for the SARS-CoV-2 infection

MAY

The New England Journal of Medicine publishes an outstanding review article signed by Vicente Arroyo, Richard Moreau and Rajiv Jalan with the most recent findings in ACLF

JULY

The EASL Clif Consortium reached it’s highest number of partners: 114

NOVEMBER

The EF Clif collaborates with the most relevant international liver transplant societies, the ILTS and the ELITA, to sponsor and launch the CHANCE Study, the first worldwide study on survival of liver transplantation in patients with ACLF